Our Initial Story....#smallbiz #RubixStrategies #biotech
of how we became what is now known as Rubix Strategies, often tells an illuminating back story. In August of 2013, the founder worked day and night to try and find a steadfast approach to treating lymphatic disease since his father's passing. After working tirelessly for 74 days, the initial combination device was born. Otherwise known as "Streetcar", this device was built around the concept of fusion injection for protein regeneration.
After some initial failures of premature material degradation binding with our pharmacological agent, we tailored our approach in a new discipline, that factors of product development were tolerated to withstand chemistry dissemination. That lead us to targeting orthopedic diseases.